ES2925115T3 - Compuestos tricíclicos para uso en el tratamiento de trastornos proliferativos - Google Patents
Compuestos tricíclicos para uso en el tratamiento de trastornos proliferativos Download PDFInfo
- Publication number
- ES2925115T3 ES2925115T3 ES18711927T ES18711927T ES2925115T3 ES 2925115 T3 ES2925115 T3 ES 2925115T3 ES 18711927 T ES18711927 T ES 18711927T ES 18711927 T ES18711927 T ES 18711927T ES 2925115 T3 ES2925115 T3 ES 2925115T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- phenyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704325.8A GB201704325D0 (en) | 2017-03-17 | 2017-03-17 | Compounds |
| PCT/EP2018/056675 WO2018167276A1 (en) | 2017-03-17 | 2018-03-16 | Tricyclic compounds for use in treatment of proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2925115T3 true ES2925115T3 (es) | 2022-10-13 |
Family
ID=58688220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18711927T Active ES2925115T3 (es) | 2017-03-17 | 2018-03-16 | Compuestos tricíclicos para uso en el tratamiento de trastornos proliferativos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11274098B2 (enExample) |
| EP (1) | EP3596073B1 (enExample) |
| JP (1) | JP7308765B2 (enExample) |
| KR (1) | KR102604942B1 (enExample) |
| CN (1) | CN110621675B (enExample) |
| CA (1) | CA3056726A1 (enExample) |
| ES (1) | ES2925115T3 (enExample) |
| GB (1) | GB201704325D0 (enExample) |
| WO (1) | WO2018167276A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| KR102282712B1 (ko) * | 2019-08-09 | 2021-07-27 | 한국화학연구원 | 신규한 피리미딘 설폰아마이드 유도체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| WO2021029450A1 (ko) * | 2019-08-09 | 2021-02-18 | 한국화학연구원 | 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| KR102278691B1 (ko) * | 2019-08-09 | 2021-07-16 | 한국화학연구원 | 신규한 피리미딘 설폰아마이드 유도체 |
| WO2021066578A1 (ko) | 2019-10-02 | 2021-04-08 | 에스케이바이오팜 주식회사 | 바이사이클릭 화합물 및 이의 용도 |
| CN111454260B (zh) * | 2020-05-25 | 2023-02-28 | 贵州大学 | 一类含异丙醇胺亚结构的1，2，3，4-四氢-β-咔啉类化合物及其制备方法和应用 |
| CN111892593B (zh) * | 2020-08-19 | 2021-11-16 | 南通大学 | 一种8-甲氧基-5H-吡啶并[4,3-b]吲哚及其合成方法 |
| CN117062816A (zh) * | 2021-02-04 | 2023-11-14 | 美国安进公司 | 三环-酰胺-双环prmt5抑制剂 |
| CN113105517B (zh) * | 2021-04-10 | 2022-03-01 | 台州仙琚药业有限公司 | 雄甾-1,4,9-三烯-3,17-二酮的合成方法 |
| GB202108383D0 (en) * | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN115521306B (zh) * | 2022-09-26 | 2024-03-26 | 贵州大学 | 一种1,2,3,4-四氢-β-咔啉衍生物及其制备方法和应用 |
| CN117088891B (zh) * | 2023-07-13 | 2026-06-16 | 浙江大学 | 含四氢苯并[4,5]呋喃[2,3-c]吡啶类羟肟酸化合物及其制备方法和应用 |
| CN121226371B (zh) * | 2025-10-28 | 2026-07-14 | 百色学院 | 四氢吡嗪[1,2-a]吲哚类组蛋白去乙酰化酶抑制剂及其制备方法与应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3317524A (en) * | 1965-02-04 | 1967-05-02 | American Home Prod | Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles |
| US3687961A (en) * | 1971-05-03 | 1972-08-29 | Abbott Lab | 8-fluoro-2-{8 3-(4-fluorophenylanilinopropyl{9 -gamma-carboline |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| DE2854014A1 (de) * | 1978-12-14 | 1980-07-03 | Troponwerke Gmbh & Co Kg | 7,8,9,10-tetrahydrothieno eckige klammer auf 3,2-e eckige klammer zu pyrido eckige klammer auf 4,3-b eckige klammer zu indole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4719211A (en) | 1984-05-01 | 1988-01-12 | American Home Products Corporation | 2,3,4,9-tetrahydro-2-heteroarylalkyl-1H-pyrido(3,4-B)indoles having antihypertensive properties |
| SU1248223A1 (ru) * | 1985-01-07 | 1995-09-20 | Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений | ДИГИДРОХЛОРИД 2-(3-ИЗОПРОПИЛАМИНО-2-ГИДРОКСИПРОПИЛ)-1,2,3,4-ТЕТРАГИДРО- β -КАРБОЛИНА, ОБЛАДАЮЩИЙ АНТИАЛКОГОЛЬНЫМ И ПСИХОТРОПНЫМ ДЕЙСТВИЕМ |
| US4663456A (en) * | 1985-09-16 | 1987-05-05 | American Home Products Corporation | 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| UA52681C2 (uk) | 1997-04-08 | 2003-01-15 | Янссен Фармацевтика Н.В. | Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP0905136A1 (en) | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| NZ555491A (en) | 2005-01-03 | 2010-01-29 | Univ Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| US20070213359A1 (en) | 2005-12-30 | 2007-09-13 | Acadia Pharmaceuticals Inc. | Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof |
| US8853391B2 (en) | 2008-12-18 | 2014-10-07 | Merck Patent Gmbh | Tricyclic azaindoles |
| JP2016505002A (ja) * | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| AU2014205065A1 (en) | 2013-01-14 | 2015-07-30 | Ent Associates Of Los Alamos, Llc | Honey nasal rinse |
| US9879015B2 (en) | 2013-04-23 | 2018-01-30 | Laboratorios Del Dr. Esteve S.A. | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments |
| JP6388456B2 (ja) | 2013-06-28 | 2018-09-12 | アルツプロテクト | 神経変性疾患の治療に使用可能なカルボリン化合物 |
| US10662193B2 (en) * | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| US20170107229A1 (en) | 2014-05-26 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | Substituted tetrahydropyridothienopyrimidines |
| EP3160466A4 (en) * | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| AU2015301196A1 (en) * | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
-
2017
- 2017-03-17 GB GBGB1704325.8A patent/GB201704325D0/en not_active Ceased
-
2018
- 2018-03-16 CN CN201880031972.3A patent/CN110621675B/zh active Active
- 2018-03-16 EP EP18711927.6A patent/EP3596073B1/en active Active
- 2018-03-16 ES ES18711927T patent/ES2925115T3/es active Active
- 2018-03-16 JP JP2019571789A patent/JP7308765B2/ja active Active
- 2018-03-16 CA CA3056726A patent/CA3056726A1/en active Pending
- 2018-03-16 WO PCT/EP2018/056675 patent/WO2018167276A1/en not_active Ceased
- 2018-03-16 US US16/494,570 patent/US11274098B2/en active Active
- 2018-03-16 KR KR1020197029438A patent/KR102604942B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7308765B2 (ja) | 2023-07-14 |
| US11274098B2 (en) | 2022-03-15 |
| GB201704325D0 (en) | 2017-05-03 |
| CN110621675A (zh) | 2019-12-27 |
| US20200325132A1 (en) | 2020-10-15 |
| CN110621675B (zh) | 2023-09-19 |
| CA3056726A1 (en) | 2018-09-20 |
| EP3596073A1 (en) | 2020-01-22 |
| EP3596073B1 (en) | 2022-05-11 |
| KR102604942B1 (ko) | 2023-11-21 |
| WO2018167276A1 (en) | 2018-09-20 |
| KR20190129071A (ko) | 2019-11-19 |
| JP2020510092A (ja) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102604942B1 (ko) | 증식성 장애의 치료에 사용하기 위한 트리사이클릭 화합물 | |
| CN110650950B (zh) | 用于治疗或预防prmt5介导的疾病的化合物 | |
| CN112094269B (zh) | 一类饱和六元环并杂环类化合物、制备方法和用途 | |
| ES2975661T3 (es) | Inhibidores de BCL6 derivados de la 2-quinolona | |
| JP2025016684A (ja) | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 | |
| EP4630426A2 (en) | Triazole compounds, preparation methods and medicinal uses thereof | |
| ES2818620T3 (es) | Derivados de azabencimidazol como inhibidores de pi3k beta | |
| ES2775449T3 (es) | Nuevos derivados de cianoindolina sustituida como inhibidores de nik | |
| ES3047908T3 (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as blc6 inhibitors | |
| WO2018228275A1 (zh) | 作为mnk抑制剂的杂环化合物 | |
| ES2926641T3 (es) | Derivados de N2-fenil-pirido[3,4-d]pirimidin-2,8-diamina y su uso como inhibidores de MPS1 | |
| EP3697784A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2026509311A (ja) | Ｄｎａポリメラーゼシータの阻害剤 | |
| ES2877140T3 (es) | Derivados de pirimidinona como inhibidores de Cdc7 | |
| WO2023226964A1 (en) | Heterocyclic derivatives, compositions and uses thereof | |
| US20230045929A1 (en) | Isoquinoline derivatives as sik2 inhibitors | |
| US12509457B2 (en) | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | |
| CN120858100A (zh) | 抑制性化合物 | |
| WO2021084265A1 (en) | Isoquinoline derivatives as sik2 inhibitors | |
| ES2845048T3 (es) | Preparación y usos de derivados de pirimidinona | |
| BR112019019358B1 (pt) | Compostos, composição farmacêutica, uso dos referidos compostos, método in vitro para alterar a expressão gênica em uma célula e combinação compreendendo um composto |